FDA Approves Extended Prevymis Regimen for HSCT Patients at Risk of Late CMV
The FDA has approved extending the use of CMV prophylaxis with Prevymis (letermovir) from 100 days to 200 days post-transplant.
Diagnosis & Disease Information
Experimental GVHD Prophylaxis Outperforms Standard Prophylaxis
Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil provides benefits over standard GVHD prophylaxis, a phase 3 study suggests.
FDA Approves Omisirge for Blood Cancer Patients Undergoing Cord Blood Transplant
Omisirge is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.
Residual Variants May Predict Relapse, Death in AML
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Iomab-B Enables ASCT in AML Patients Typically Not Eligible for Transplant
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Posoleucel Deemed Effective Against Viral Infections in Allogeneic HSCT Recipients
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Outcomes Superior With Peripheral Blood vs Bone Marrow Transplants in PTCL
Researchers observed improvements in overall survival and progression-free survival with peripheral blood vs bone marrow transplants.
Delaying HSCT More Than 4 Weeks After COVID-19 Diagnosis May Decrease Risk of Death
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.
PTCy Plus Tacrolimus and MMF “Should Be Standard” GVHD Prophylaxis in RIC PBSCT
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
- Loading...
Loading...
Next post in ASH 2022
Loading... 
Loading...